Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD) [clinicaltrials:NCT01910662]

Bio2RDF uri

Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD) [clinicaltrials:NCT01910662]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT01910662

Bio2RDF identifier

NCT01910662

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01910662

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

This is an exploratory ...... plus up to 30 days screening.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Characterisation of T-cell Res ...... ified Protein Derivative (PPD)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:4b97706aa52f8b595bab173b0ff90b9c]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:5e9901a8575417f6c507b16307e4b537]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:6a1bb780e7f078b29f050f3413cb93d6]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:b0bcde7cbd1c44c54b69db1dee33fb6c]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:fa968451dbedc9365bd7cfabf5f6d712]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:16ea7ea64535ba9c8abae519d0d49b75]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:1f9da7ccb1934717bbde30b7170f5b18]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:2698feb0b6180b440839b500fc6e2451]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:2ff74192e22315a2c12230a950ec5bb4]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:3666e8a03b19b396099f4cbc9b8443ed]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:382f6b18744fef95072594c300090313]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:48b763b24df9266ad3c1f8c1a24a765b]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:50ec93afa5215eb1cfaf969e618caf41]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:8f24b95871b0596de7530a91d85ef4d3]

Part A: Skin inflammatory response measurement as induration by the ball point pen technique Over a four day period after challenge [clinicaltrials_resource:9071b734aed3c55f987aee738831f6b8]

completion date [clinicaltrials_vocabulary:completion-date]

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Dermatitis [clinicaltrials_resource:f3898163355388a4d9c3a8a19b300964]

condition browse [clinicaltrials_vocabulary:condition-browse]

Hypersensitivity, Delayed [clinicaltrials_resource:6a56faa204e6c5af872eb1607346d435]

Hypersensitivity [clinicaltrials_resource:825a2f78cd33d00e9ddf274e1e55e0dd]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Hypersensitivity, Delayed [clinicaltrials_resource:6a56faa204e6c5af872eb1607346d435]

Hypersensitivity [clinicaltrials_resource:825a2f78cd33d00e9ddf274e1e55e0dd]

country [clinicaltrials_vocabulary:country]

United Kingdom [clinicaltrials_resource:89f9c9f489be2a83cf57e53b9197d288]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01910662 [clinicaltrials_resource:49153b6bef1daa1a705018400a0a9541]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2013-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

PBS (0.1 mL) [clinicaltrials_resource:69121f331bb06fd5e2f4fbe34c054329]

KLH 5 mg [clinicaltrials_resource:6f1769e566d94dee5f6484d107a098f5]

Tuberculin PPD [clinicaltrials_resource:7e8b238215cc9f6ac3b2ad667c3f151f]

KLH 0.1 mg [clinicaltrials_resource:8b7f92d636f5b85631950cc208306de1]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Keyhole-limpet hemocyanin [clinicaltrials_resource:d5ef4ca1260d86c18818dd4693482af2]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Biopsy

http://www.w3.org/2001/XMLSchema#string

Delayed Type Hypersensitivity

http://www.w3.org/2001/XMLSchema#string

Erythema

http://www.w3.org/2001/XMLSchema#string

Induration

http://www.w3.org/2001/XMLSchema#string

Keyhole Limpet Hemocyanin

http://www.w3.org/2001/XMLSchema#string

Suction Skin Blister

http://www.w3.org/2001/XMLSchema#string

Tuberculin Purified Protein Derivative

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2013-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

location [clinicaltrials_vocabulary:location]

GSK Investigational Site [clinicaltrials_resource:dc5881f0c915a78ee3b5ea289a61b534]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01910662

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Characterisation of the T-cell ...... ve (PPD) in Healthy Volunteers

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

117.249

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

GSK Clinical Trials [clinicaltrials_resource:482ca15ed5613e7d70d0185ac9204ca5]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United Kingdom: Medicines and Healthcare Products Regulatory Agency [clinicaltrials_resource:a8b63bccf34b2b6d3a8ea2423e6b7a0f]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

start date [clinicaltrials_vocabulary:start-date]

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01910662 study design [clinicaltrials_resource:9b7e811639b8281f8e72020e9c0ec677]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01910662

verification date [clinicaltrials_vocabulary:verification-date]

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01910662

http://www.w3.org/2001/XMLSchema#string

title

Characterisation of T-cell Res ...... ified Protein Derivative (PPD)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Characterisation of T-cell Res ...... ) [clinicaltrials:NCT01910662]

@en